We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
To determine whether an electronic document management system (EDMS) requires validation, companies should identify the regulatory and/or business risk the system poses to product safety, efficacy and quality, according to an industry expert.
The key to adhering to a predicate rules-based system for GMP and using a risk-based approach for computer system compliance successfully is to understand how systems are being used as part of the entire process, understanding if and how your company is relying on the system and understanding the impact of the system, according to an industry expert.
The Good Automated Manufacturing Practice (GAMP) Forum, a division of the International Society for Pharmaceutical Engineering (ISPE), has released its "GAMP Good Practice Guide: A Risk-Based Approach to Compliant Electronic Records and Signatures."
The Good Automated Manufacturing Practice (GAMP) Forum, a division of the International Society for Pharmaceutical Engineering (ISPE), will release its “GAMP Good Practice Guide: Risk Management Approach to Electronic Records and Signatures,” on Feb. 18 at an ISPE conference in Tampa, Fla.
Despite cries from some industry groups to kill 21 CFR Part 11, the FDA isn’t likely to take such a drastic step, according to a former FDA policymaker.
Janssen Pharmaceutica has selected ABB to install a Part 11-compliant manufacturing system in its new greenfield active pharmaceutical ingredient (API) plant in Cork, Ireland.
The FDA will make substantial changes to and relax some of the requirements of 21 CFR Part 11, but the controversial rule won’t go away, according to a former FDA policymaker.
Pharmaceutical companies are expected to increase information technology (IT) spending by roughly 5 percent during the next 12 months, with a majority of the investment coming in the clinical trials arena.
While a recent Citizen Petition asking the FDA to revoke 21 CFR Part 11 presents a compelling case, it does not always demonstrate that existing federal regulations are strong enough to protect electronic data and electronic signature integrity without Part 11 in place, said experts at a recent Drug Information Association (DIA) panel.
Pharmaceutical and medical device companies generally agree that the FDA is doing the right thing to reevaluate its Part 11 rule, but most firms believe that the regulation should not be wiped away completely.